103,896 results match your criteria Lung Cancer Small Cell


Combination of computed tomography-guided iodine-125 brachytherapy and bronchial arterial chemoembolization for locally advanced stage III non-small cell lung cancer after failure of concurrent chemoradiotherapy.

Lung Cancer 2020 Jun 20;146:290-296. Epub 2020 Jun 20.

Department of Interventional Medicine, The Second Hospital, Cheeloo College of Medicine, Shandong University, China; Interventional Oncology Institute of Shandong University, China. Electronic address:

Objectives: To evaluate the efficacy and safety of the combination of computed tomography (CT)-guided iodine-125 brachytherapy and bronchial arterial chemoembolization (BACE) for locally advanced stage III non-small cell lung cancer (NSCLC) after failure of concurrent chemoradiotherapy.

Material And Methods: We retrospectively evaluated 28 patients with locally advanced stage III NSCLC in whom concurrent chemoradiotherapy had failed and were consequently, treated with radioactive iodine-125 seed implantation followed by BACE. The prescribed radiation dose was 140 Gy, with a median radioactivity of 0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2020.06.010DOI Listing

Proton beam or photon beam radiotherapy in the treatment of non-small-cell lung cancer.

Lancet Oncol 2020 Jul;21(7):873-875

Radiation Oncology, Tor Vergata University, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(20)30246-1DOI Listing

The Academic Facility Type is Associated with Improved Overall Survival for Early Stage Lung Cancer.

Ann Thorac Surg 2020 Jun 29. Epub 2020 Jun 29.

Thoracic Surgery Division, The Ohio State University Wexner Medical Center, Columbus, OH.

Background: Early stage Non-small cell lung cancer (NSCLC) is potentially curable with surgical resection. The overall survival rate for early stage NSCLC may be determined by the healthcare facility type where patients receive their lung cancer treatment.

Methods: A total of 103,748 cases with the American Joint Committee on Cancer (AJCC) clinical stage I and II NSCLC that were reported to the National Cancer Database at over 1,150 facilities were analyzed in this study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.athoracsur.2020.05.051DOI Listing

Clinical impacts of EGFR mutation status: analysis of 5,780 surgically resected lung cancer cases.

Ann Thorac Surg 2020 Jun 29. Epub 2020 Jun 29.

Department of General Thoracic Surgery, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8677, Japan.

Background: To elucidate the clinical, pathologic, and prognostic impacts of EGFR mutation and mutation subtypes in early-stage lung cancer, we conducted a retrospective analysis of the Japanese Joint Committee of Lung Cancer Registry database (a nationwide database for surgically-resected lung cancer patients; n = 18,973).

Methods: Of 13,951 patients classified as non-squamous non-small cell lung cancer in the database, 5,780 patients (41.0%) had been tested for EGFR mutation and were included in this study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.athoracsur.2020.05.041DOI Listing

circMET promotes NSCLC cell proliferation, metastasis, and immune evasion by regulating the miR-145-5p/CXCL3 axis.

Aging (Albany NY) 2020 Jul 2;12. Epub 2020 Jul 2.

Department of Cardiothoracic Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.

In recent years, circular RNAs (circRNAs) have been increasingly reported to play a crucial role in the proliferation, migration, and invasion of non-small-cell lung cancer (NSCLC) cells. However, the circRNA MET (circMET) oncogenic mechanism that drives NSCLC development and progression remains largely unknown. In this study, the present results demonstrated that circMET expression was significantly higher in NSCLC tissues than in peritumoral tissues using quantitative real-time polymerase chain reaction. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/aging.103392DOI Listing

Pyrotinib in -Mutant Advanced Lung Adenocarcinoma After Platinum-Based Chemotherapy: A Multicenter, Open-Label, Single-Arm, Phase II Study.

J Clin Oncol 2020 Jul 2:JCO2000297. Epub 2020 Jul 2.

Jiangsu Hengrui Medicine Co, Ltd, Shanghai, China.

Purpose: Targeted therapies against non-small-cell lung cancer (NSCLC) harboring mutations remain an unmet need. In this study, we assessed the efficacy and safety of pyrotinib in patients with -mutant advanced NSCLC in a prospective, multicenter, open-label, single-arm, phase II study.

Patients And Methods: Patients with stage IIIB or IV -mutant lung adenocarcinoma who were previously treated with platinum-based chemotherapy were enrolled to receive pyrotinib at a dose of 400 mg/d for 21-day cycles. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.20.00297DOI Listing

Diagnosis and Treatment of Metastatic Disease to the Pancreas.

J Laparoendosc Adv Surg Tech A 2020 Jul 1. Epub 2020 Jul 1.

Department of Surgery, Mount Sinai Medical Center, Comprehensive Cancer Center, Miami Beach, Florida, USA.

Metastatic disease to the pancreas is a rare entity from all malignant pancreatic masses. Its diagnosis is very challenging, but with the introduction of endoscopic ultrasound (EUS)-fine needle aspiration (FNA), now there is a feasible way to make an accurate histopathological and definitive diagnosis. This is a retrospective review of 11 patients with metastasis to the pancreas diagnosed with EUS-FNA in a tertiary referral center over a period of 3 years. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/lap.2020.0219DOI Listing

Magnetic Synthetic Receptors for Selective Clean-Up in Protein Biomarker Quantification.

J Proteome Res 2020 Jul 2. Epub 2020 Jul 2.

Biomarker analysis by mass spectrometry (MS) can allow for the rapid quantification of low abundance biomarkers. However, the complexity of human serum is a limiting factor in MS-based bioanalysis, therefore, novel biomarker enrichment strategies are of interest, particularly if the enrichment strategies are of low cost and are easy to use. One such strategy involves the use of molecularly imprinted polymers (MIPs) as synthetic receptors for biomarker enrichment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/acs.jproteome.0c00258DOI Listing

Synergistic effects of extracellular vesicle phenotyping and AFP in hepatobiliary cancer differentiation.

Liver Int 2020 Jul 2. Epub 2020 Jul 2.

Department of Medicine II, Saarland University Medical Center, Saarland University, Homburg, Germany.

Background: Biliary cancer, comprising cholangio- and gallbladder carcinomas, is associated with high mortality due to asymptomatic disease onset and resulting late diagnosis. Currently, no robust diagnostic biomarker is clinically available. Therefore, we explored the feasibility of extracellular vesicles (EVs) as a liquid biopsy tool for biliary cancer screening and hepatobiliary cancer differentiation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/liv.14585DOI Listing

Genetic variants in the human leukocyte antigen region and survival of Chinese patients with non-small-cell lung carcinoma.

Carcinogenesis 2020 Jul 2. Epub 2020 Jul 2.

Cancer Institute, Collaborative Innovation Center for Cancer Medicine, Shanghai, China.

Human leukocyte antigen (HLA) is highly polymorphic, driving antigen presentation, complement cascade, and leukocyte maturation against cancer cells. Therefore, we extracted genotyping data in the HLA region from an ongoing Chinese genome-wide association study of non-small cell lung cancer (NSCLC). Using deep sequencing data of 10,689 healthy Han Chinese, we imputed the HLA region, followed by a two-stage survival analysis of 1,531 NSCLC patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/carcin/bgaa066DOI Listing

High Biologically Effective Dose Radiotherapy for Brain Metastases May Improve Survival and Decrease Risk for Local Relapse Among Patients With Small-Cell Lung Cancer: A Propensity-Matching Analysis.

Cancer Control 2020 Apr-Jun;27(2):1073274820936287

Department of Radiation Oncology, Fujian Cancer Hospital, Fujian Medical University Cancer Hospital, Fuzhou, China.

To evaluate whether high biologically effective dose (BED) radiotherapy improves local control and survival outcomes for patients with brain metastases (BMs) from small-cell lung cancer (SCLC) and to determine possible prognostic factors. From January 1998 to June 2018, 250 patients with BM from SCLC were retrospectively analyzed. The Cutoff Finder program was used to classify patients by BED. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1073274820936287DOI Listing

Simultaneous response of cutaneous and lung squamous cell carcinoma with cemiplimab.

Dermatol Ther 2020 Jul 2:e13951. Epub 2020 Jul 2.

Department of Dermatology - Centre Hospitalier Universitaire de Nancy, Nancy, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/dth.13951DOI Listing

[Clinical management of rheumatic immune-related adverse events : Recognize and treat rheumatological side effects of checkpoint inhibition].

Authors:
K Benesova J Leipe

Z Rheumatol 2020 Jul 1. Epub 2020 Jul 1.

Sektion Rheumatologie, V. Medizinische Klinik, Universitätsklinik Mannheim, Mannheim, Deutschland.

Immune checkpoint inhibitors (ICPi) represent a major breakthrough in the treatment and prognosis of many cancers, particularly of malignant melanoma and non-small cell lung cancer; however, the high tumor response rates with ICPi are also frequently associated with autoimmune side effects, so-called immune-related adverse events (irAEs), which can involve virtually any organ system and mirror classical autoimmune diseases. Recent studies revealed that around 5-20% of patients treated with ICPi experience rheumatic irAEs covering the full spectrum of inflammatory rheumatic diseases. This article summarizes the state of the art of knowledge with respect to diagnostics and management of this newly recognized disease entity in rheumatology. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00393-020-00825-zDOI Listing

Added value of invasive needle techniques in mediastinal and hilar nodal staging of clinical N0-N1 non-small cell lung cancer after positron emission tomography.

Clin Transl Radiat Oncol 2020 Sep 18;24:49-51. Epub 2020 Jun 18.

Department of Pulmonary Medicine and Thoracic Surgery, Quebec Heart and Lung Institute, Quebec, Canada.

Previous studies evaluating staging methods of lung cancer have focused on mediastinal disease. We explored the added value of endoscopic techniques after PET scan in the evaluation of N1 nodal stations in 276 patients with a radiologically normal mediastinum demonstrating a potential stage shift in 20% of patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctro.2020.06.009DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7320229PMC
September 2020

Cryptotanshinone attenuates the stemness of non-small cell lung cancer cells via promoting TAZ translocation from nuclear to cytoplasm.

Chin Med 2020 30;15:66. Epub 2020 Jun 30.

Department of Respiratory & Critical Care Medicine, Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Rd, Nanjing, 210029 People's Republic of China.

Background: Cancer stem cells (CSCs) are regarded as the root of tumor progression, thus representing an anti-cancer therapy through targeting this cell sub-population.

Methods: Non-small cell lung cancer (NSCLC) CSCs were enriched by non-adherent spheroid formation analysis. Lentivirus infection was used to stably change gene expression. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13020-020-00348-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7325009PMC

Preparation of RGD Peptide/Folate Acid Double-Targeted Mesoporous Silica Nanoparticles and Its Application in Human Breast Cancer MCF-7 Cells.

Front Pharmacol 2020 16;11:898. Epub 2020 Jun 16.

Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, China.

Pharmacological Relevance: Paclitaxel (PTX) is currently the only botanical drug that can control the growth of cancer cells. Paclitaxel is widely used in the treatment of breast cancer, ovarian cancer, uterine cancer, non-small cell lung cancer and other cancers.

Aim: Folate receptor and integrin are highly expressed on the surface of human breast cancer cells MCF-7. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fphar.2020.00898DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7309969PMC

Pulmonary Adenocarcinoma Presenting as a Pineal Gland Mass With Obstructive Hydrocephalus.

Ochsner J 2020 ;20(2):232-235

Department of Internal Medicine, University of South Dakota Sanford School of Medicine, Sioux Falls, SD.

Adenocarcinoma is the most prevalent type of non-small cell carcinoma of the lungs. Patients with lung adenocarcinoma often present with cough, dyspnea, pain, and weight loss. They can also present with signs and symptoms of brain metastasis because the lungs are one of the most common origins of metastatic brain cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.31486/toj.18.0159DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7310168PMC
January 2020

Determination of Endothelial Nitric Oxide Synthase Gene Polymorphism and Plasma Asymmetric Dimethyl Arginine Concentrations in Patients with Lung Cancer.

Eurasian J Med 2020 Jun 5;52(2):185-190. Epub 2020 Jun 5.

Department of Biochemistry, Yuzuncu Yil University School of Medicine, Van, Turkey.

Objective: Genetic factors can contribute to both the occurrence and development of lung cancer. This study aimed to investigate endothelial nitric oxide synthase (eNOS) G894T and T-786C polymorphisms and plasma asymmetric dimethylarginine (ADMA) levels of lung cancer patients in comparison with healthy subjects.

Materials And Methods: A total of 200 subjects, 100 patients with lung cancer and 100 healthy volunteers were included in this study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5152/eurasianjmed.2020.19220DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7311131PMC

Nitrative DNA damage in lung epithelial cells exposed to indium nanoparticles and indium ions.

Sci Rep 2020 Jul 1;10(1):10741. Epub 2020 Jul 1.

Department of Environmental and Molecular Medicine, Mie University Graduate School of Medicine, Tsu, Mie, Japan.

Indium compounds have been widely used in manufacturing displays of mobile phones, computers and televisions. However, inhalation exposure to indium compounds causes interstitial pneumonia in exposed workers and lung cancer in experimental animals. 8-Nitroguanine (8-nitroG) is a mutagenic DNA lesion formed under inflammatory conditions and may participate in indium-induced carcinogenesis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-020-67488-3DOI Listing

Treatment Rationale and Design of a Phase III Study of Afatinib or Chemotherapy in Patients with Non-small-cell Lung Cancer Harboring Sensitizing Uncommon Epidermal Growth Factor Receptor Mutations (ACHILLES/TORG1834).

Clin Lung Cancer 2020 May 21. Epub 2020 May 21.

Department of Internal Medicine, Niigata Cancer Center Hospital, Niigata, Japan.

We describe the treatment rationale and design of our randomized phase III study, the ACHILLES trial (Japan Registry of Clinical Trials: jRCTs031180175). The aim of this study is to investigate the superiority of afatinib over chemotherapy as first-line treatment in patients with advanced nonsquamous non-small-cell lung cancer with sensitizing uncommon or compound epidermal growth factor receptor (EGFR) mutations, with the exception of de novo T790M mutations and exon 20 insertions. Eligible patients will be randomized at a 1:2 ratio to receive either chemotherapy or afatinib until disease progression or unacceptable toxicity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2020.05.011DOI Listing

Over-expression of long non-coding RNA ZEB2-AS1 may predict poor prognosis and promote the migration, invasion, and epithelial-mesenchymal transition of tumor cells in non-small cell lung cancer.

Int J Biol Markers 2020 Jul 2:1724600820938385. Epub 2020 Jul 2.

Department of Thoracic Surgery, Ningbo Medical Center Lihuili Hospital, Ningbo, Zhejiang, China.

Background: Non-small cell lung cancer (NSCLC) remains the most common cause of human cancer-related death worldwide, and the present study aims to explore the roles of long non-coding (lnc)RNA ZEB2-AS1 in NSCLC and the related mechanism.

Methods: Quantitative real-time-polymerase chain reaction was performed to compare the expressions of ZEB2-AS1 in NSCLC cancer tissue and the adjacent non-tumorous tissues. The diagnostic and prognostic roles of ZEB2-AS1 in NSCLC were also evaluated by the receiver operating characteristic curve and the Kaplan-Meier survival analysis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1724600820938385DOI Listing

Robust treatment planning with 4D intensity modulated carbon ion therapy for multiple targets in stage IV non-small cell lung cancer.

Phys Med Biol 2020 Jul 1. Epub 2020 Jul 1.

Biophysik, GSI Helmholtzzentrum für Schwerionenforschung GmbH, Darmstadt, GERMANY.

Purpose: Intensity modulated particle therapy (IMPT) with carbon ions can generate highly conformal treatment plans; however, IMPT is limited in robustness against range and positioning uncertainty. This is particularly true for moving targets, even though all motion states of a 4DCT are considered in 4D-IMPT. Here, we expand 4D-IMPT to include robust non-linear RBE-weighted optimization to explore its potential in improving plan robustness and sparing critical organs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1088/1361-6560/aba1a3DOI Listing

Chemoradiotherapy efficacy is predicted by intra-tumour CD8+/FoxP3+ double positive T cell density in locally advanced N2 non-small-cell lung carcinoma.

Eur J Cancer 2020 Jun 28;135:221-229. Epub 2020 Jun 28.

Institut National de La Santé et de La Recherche Médicale (INSERM), UMRS 1138, Cordeliers Research Center, Team Cancer, inflammation and complement, Paris, France; University Paris Descartes, Paris, France; University Pierre et Marie Curie-Paris, Paris, France; Department of Pathology, Assistance Publique - Hôpitaux de Paris (AP-HP), Hôpital Cochin, Paris, France. Electronic address:

Background: Radiotherapy is a standard of care for locally advanced stage III N2 non-small-cell lung carcinoma (NSCLC) combined with surgery/chemotherapy. Radiotherapy is hypothesised to induce tumour immunogenic cell death, to release neoantigen resulting in intra-tumoural immune infiltration and abscopal effect. Conversely, it has not been demonstrated if immune cells are necessary to drive radiotherapy efficacy and predict patient's survival. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2020.04.040DOI Listing

Quantifying the interfractionalmotion of esophagus using daily cone beam computed tomography with oral contrast during radiotherapy for locally advanced non-small cell lung cancer.

Pract Radiat Oncol 2020 Jun 28. Epub 2020 Jun 28.

State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong 510060, P. R. China; Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong 510060, P. R. China; GuangDong Association Study of Thoracic Oncology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong 510060, P. R. China; Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong 510060, P. R. China. Electronic address:

Background: and Purpose: To quantify the interfractional motion of the esophagus during fractionated radiotherapy for locally advanced non-small cell lung cancer (NSCLC).

Materials And Methods: We registered simulation four-dimensional computed tomography (4DCT) and daily cone beam CT (CBCT), and documented the motion of the esophagus centroid at 5mm-interval slices in right-left (RL) and anterior-posterior (AP) directions. Oral barium sulfate was administrated during CBCT to help localize the esophagus. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.prro.2020.06.006DOI Listing

FDA Approves 2 Therapies for Treatment of Metastatic Non-Small Cell Lung Cancer.

Authors:
Kevin M Wright

Oncology (Williston Park) 2020 Jun;34(6):202

The FDA approved 2 new therapies, each with its own companion diagnostic, for the treatment of patients with metastatic non-small cell lung cancer. Read More

View Article

Download full-text PDF

Source

Inequity in access to personalized medicine in France: Evidences from analysis of geo variations in the access to molecular profiling among advanced non-small-cell lung cancer patients: Results from the IFCT Biomarkers France Study.

PLoS One 2020 1;15(7):e0234387. Epub 2020 Jul 1.

Aix-Marseille Univ., CNRS, EHESS, Centrale Marseille, AMSE, Marseille, France.

In this article, we studied geographic variation in the use of personalized genetic testing for advanced non-small cell lung cancer (NSCLC) and we evaluated the relationship between genetic testing rates and local socioeconomic and ecological variables. We used data on all advanced NSCLC patients who had a genetic test between April 2012 and April 2013 in France in the frame of the IFCT Biomarqueurs-France study (n = 15814). We computed four established measures of geographic variation of the sex-adjusted rates of genetic testing utilization at the "départment" (the French territory is divided into 94 administrative units called 'départements') level. Read More

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0234387PLOS

A Network Pharmacology Approach to Explore the Potential Mechanisms of Huangqin-Baishao Herb Pair in Treatment of Cancer.

Med Sci Monit 2020 Jul 1;26:e923199. Epub 2020 Jul 1.

School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China (mainland).

BACKGROUND The aim of this study was to identify the bioactive ingredients of Huangqin-Baishao herb pair and to reveal its anti-cancer mechanisms through a pharmacology approach. MATERIAL AND METHODS Detailed information on compounds in the HQ-BS herb pair was obtained from the Traditional Chinese medicine systems pharmacology (TCMSP) and screened by the criteria of OB ≥30% and DL ≥0.18. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12659/MSM.923199DOI Listing

Az első száz minimálisan invazív tüdőlebeny-eltávolítás eredményei osztályunk beteganyagában.

Magy Seb 2020 Jun;73(2):57-60

Sebészeti Osztály,Bács-Kiskun megyei Kórház, Bács-Kiskun megyei Kórház, Sebészeti Osztály, 6000 Kecskemét, Nyíri út 38.

Patients And Methods: Between 1st November 2013 and 30th June 2019 we performed 112 VATS lobectomies with isolated intubation and anterior approach. In 98 cases lobectomies were performed for malignant lesions, while in 9 cases for benign changes. 78 men and 34 women were operated on. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1556/1046.73.2020.2.2DOI Listing

Ectopic Cushing syndrome in Colombia.

Arch Endocrinol Metab 2020 Jun 29. Epub 2020 Jun 29.

Departamento de Neoplasia Endocrina y Trastornos Hormonales, Universidad de Texas, MD Anderson Cancer Center, Houston Texas.

Objective: The aim was to describe the clinical features of patients with ectopic Cushing syndrome (ECS) from Colombia and compare these findings with other series to provide the best management for these patients.

Materials And Methods: Records of patients with ECS from 1986 to 2017 were retrospectively reviewed; patients with a diagnosis of adrenal or pituitary Cushing syndrome (CS) were excluded.

Results: Fourteen patients with ECS were analyzed in this study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.20945/2359-3997000000271DOI Listing

Development of triple mutant T790M/C797S allosteric EGFR inhibitors: a computational approach.

J Biomol Struct Dyn 2020 Jul 1:1-23. Epub 2020 Jul 1.

Department of Chemical Technology, Dr. Babasaheb Ambedkar Marathwada University, Aurangabad, India.

The mutations concerned with non-small cell lung cancer involving epidermal growth factor receptor of tyrosine kinase family have primarily targeted. EGFR inhibitors binding allosterically to C797S mutant EGFR enzyme have been developed. Here, database building, library screening performing R-group enumeration and scaffold hopping technique for increasing the EGFR binding affinity of compounds have been carried out. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/07391102.2020.1786460DOI Listing

Berberine chloride suppresses non-small cell lung cancer by deregulating Sin3A/TOP2B pathway in vitro and in vivo.

Cancer Chemother Pharmacol 2020 Jun 30. Epub 2020 Jun 30.

The First Affiliated Hospital of Shenzhen University, Shenzhen Second People's Hospital, Shenzhen, 518035, China.

Purpose: Berberine chloride (BBC) is a well-known plant isoquinoline alkaloid derived from Berberis aristata. In this study, we aim to explore the effect of BBC on non-small cell lung cancer (NSCLC), and further expound the underlying mechanism of BBC induces NSCLC cell death in vitro and in vivo.

Methods: CCK-8 assay and colony formation assay were used to test the viability and colony formation ability of NSCLC cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-020-04050-yDOI Listing

Clinical characteristics and prognostic value of the mutation in Chinese non-small cell lung cancer patients.

Biomark Res 2020 25;8:22. Epub 2020 Jun 25.

Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, School of Medicine, South China University of Technology, 106 Zhongshan Er Road, Guangzhou, 510080 China.

Background: The mutation is the second most common genetic variant in Chinese non-small cell lung cancer (NSCLC) patients. At the 2019th World Conference of Lung Cancer, the -specific inhibitor AMG510 showed promising results in the phase I clinical trial. However, the frequency, clinical characteristics, and prognostic significance of the mutation in Chinese NSCLC patients are rarely reported. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40364-020-00199-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7318746PMC

Effect of Insurance Type on Stage at Presentation, Surgical Approach, Tumor Recurrence and Cancer-Specific Survival in Resectable Non-Small Lung Cancer Patients.

Risk Manag Healthc Policy 2020 12;13:559-569. Epub 2020 Jun 12.

Department of Surgery, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.

Purpose: The aim of this study was to identify the association between Thailand's insurance types and stage at presentation, surgical approach, tumor recurrence and cancer-specific survival in resectable non-small cell lung cancer (NSCLC) patients in northern Thailand.

Patients And Methods: Medical records of patients with NSCLC who underwent pulmonary resection at Chiang Mai University Hospital from January 2007 through December 2015 were retrospectively reviewed. Patients were divided into two groups: patients with the Universal Coverage Scheme (UCS) or Social Security Scheme (SSS) and patients with the Civil Servant Medical Benefit Scheme (CSMBS) or private insurance (PI). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/RMHP.S244344DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7297449PMC

Impact of Amrubicin Monotherapy as Second-Line Chemotherapy on Outcomes in Elderly Patients with Relapsed Extensive-Disease Small-Cell Lung Cancer.

Cancer Manag Res 2020 23;12:4911-4921. Epub 2020 Jun 23.

Department of Respiratory Medicine, Kitasato University School of Medicine, Sagamihara-City, Kanagawa 252-0374, Japan.

Purpose: Amrubicin (AMR) is an anticancer drug for patients with relapsed small-cell lung cancer (SCLC). However, the efficacy of AMR in elderly patients with relapsed SCLC after chemotherapy by carboplatin plus etoposide (CE) has not been sufficiently evaluated.

Patients And Methods: The medical records of patients with relapsed SCLC who received AMR as second-line chemotherapy were retrospectively reviewed, and their treatment outcomes were evaluated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CMAR.S255552DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7320750PMC

Icotinib as Adjuvant Treatment for Stage II-IIIA Lung Adenocarcinoma Patients with EGFR Mutation (ICWIP Study): Study Protocol for a Randomised Controlled Trial.

Cancer Manag Res 2020 17;12:4633-4643. Epub 2020 Jun 17.

Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, People's Republic of China.

The efficacy and possible role of epidermal growth factor receptor tyrosine kinase inhibitors in treating early-stage non-small-cell lung cancer have yet to be established. Therefore, we aimed to explore the efficacy and safety of icotinib in completely resected EGFR-mutant stage II-IIIA lung adenocarcinoma patients who underwent standard chemotherapy. This is a randomised, double-blinded, placebo-controlled, multicentre, Phase III trial. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CMAR.S240275DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7306474PMC

Multiple Immune-Related Adverse Events and Anti-Tumor Efficacy: Real-World Data on Various Solid Tumors.

Cancer Manag Res 2020 16;12:4585-4593. Epub 2020 Jun 16.

Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.

Purpose: Immune checkpoint inhibitors (ICIs) have been approved for various types of cancer; however, they cause a broad spectrum of immune-related adverse events (irAEs). The association between the development of irAEs and the clinical benefit remains uncertain. We aimed to evaluate the association of irAEs and the treatment efficacy in real-world practice. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CMAR.S247554DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7305832PMC

Economic Evaluations of Immune Checkpoint Inhibitors for Patients with Non-Small Cell Lung Cancer: A Systematic Review.

Cancer Manag Res 2020 12;12:4503-4518. Epub 2020 Jun 12.

Department of Pharmacy, Fujian Medical University Union Hospital, Fuzhou, Fujian Province, People's Republic of China.

Objective: This review aimed to assess the quality of available evidence on the economic evaluations of immune checkpoint inhibitors in patients with non-small cell lung cancer (NSCLC) and provide evidence to improve the efficiency of healthcare resources.

Materials And Methods: Literature search was performed using some electronic databases (PubMed, Embase and Cochrane Central Register of Controlled Trials). Final search was performed in December 2019. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CMAR.S248020DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7297344PMC

Inhibition of lncRNA PART1 Chemosensitizes Wild Type but Not KRAS Mutant NSCLC Cells.

Cancer Manag Res 2020 10;12:4453-4460. Epub 2020 Jun 10.

Medical Oncology Department of Thoracic Cancer 1, Cancer Hospital of China Medical University, Liaoning Cancer Hospital, Shenyang, Liaoning 110042, People's Republic of China.

Background: Lung cancer has the highest incidence among solid tumors in men and is the third most common cancer in women. Despite improved understanding of genomic and mutational landscape in non-small cell lung cancer (NSCLC), the five-year survival in these patients has remained stagnant at a dismal 15%. The first line of treatment commonly adapted for NSCLC patients with somatic mutation in is tyrosine kinase inhibitor gefitinib or erlotinib. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CMAR.S245257DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7293907PMC

A Systematic Review of Health Economic Evaluation on Targeted Therapies for First-Line Treatment of Metastatic Non-Small Cell Lung Cancer (NSCLC): Quality Evaluation.

Cancer Manag Res 2020 9;12:4357-4368. Epub 2020 Jun 9.

School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, People's Republic of China.

Background: Evolving practices in non-small cell lung cancer (NSCLC) therapy inevitably affect health care budgets, especially through the introduction of targeted therapies. This results in a rise of health economic evaluations (HEEs) in this domain. This article reviews the quality of the economic evidence of targeted therapies used in metastatic NSCLC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CMAR.S248471DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7293415PMC

Exosomal Transfer of lncRNA H19 Promotes Erlotinib Resistance in Non-Small Cell Lung Cancer via miR-615-3p/ATG7 Axis.

Cancer Manag Res 2020 8;12:4283-4297. Epub 2020 Jun 8.

Department of Medical Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan 250117, Shandong, People's Republic of China.

Background: Drug resistance restrains the effect of drug therapy in non-small cell lung cancer (NSCLC). However, the mechanism of the acquisition of drug resistance remains largely unknown. This study aims to investigate the effect of exosomal lncRNA H19 on erlotinib resistance in NSCLC and the underlying mechanism. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CMAR.S241095DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7294568PMC

Upregulated lncRNA CASC9 Contributes to Progression of Non-Small Cell Lung Cancer Through Inhibition of miR-335-3p and Activation S100A14 Expression.

Onco Targets Ther 2020 24;13:6027-6036. Epub 2020 Jun 24.

Department of Thoracic Surgery, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai 200030, People's Republic of China.

Introduction: Non-small cell lung cancer (NSCLC) is a deadly cancer type worldwide and the main sub-type of lung cancer. Cancer susceptibility candidate-9 (CASC9) was reported to be a key player in cancer progression. However, its function and underlying mechanism in NSCLC remain unclear. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/OTT.S249973DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7321690PMC

AMPK α1 Downregulates ROS Levels Through Regulating Trx Leading to Dysfunction of Apoptosis in Non-Small Cell Lung Cancer.

Onco Targets Ther 2020 23;13:5967-5977. Epub 2020 Jun 23.

Department of Respiratory Medicine, Northern Jiangsu People's Hospital, Clinical Medical College of Yangzhou University, Yangzhou, Jiangsu, People's Republic of China.

Purpose: AMP-activated protein kinase α1 (AMPK α1) associates closely with cancers. However, the relationship between AMPK α1 and non-small cell lung cancer (NSCLC) is not fully understood. In this study, we aim to explore the role and mechanism of AMPK α1 in NSCLC initiation and progression. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/OTT.S236235DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7320905PMC

Targeting the MET-Signaling Pathway in Non-Small-Cell Lung Cancer: Evidence to Date.

Onco Targets Ther 2020 17;13:5691-5706. Epub 2020 Jun 17.

University Paris-Est Créteil (UPEC), CEpiA (Clinical Epidemiology and Ageing), EA 7376- IMRB, UPEC, Créteil, France.

The c-MET proto-oncogene (MET) plays an important role in lung oncogenesis, affecting cancer-cell survival, growth and invasiveness. The MET receptor in non-small-cell lung cancer (NSCLC) is a potential therapeutic target. The development of high-output next-generation sequencing techniques has enabled better identification of anomalies in the MET pathway, like the MET exon-14 (METex14) mutation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/OTT.S219959DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7306460PMC

Erratum: Long Noncoding RNA H19 Facilitates Small Cell Lung Cancer Tumorigenesis Through miR-140-5p/FGF9 Axis [Corrigendum].

Authors:

Onco Targets Ther 2020 12;13:5493. Epub 2020 Jun 12.

[This corrects the article DOI: 10.2147/OTT.S245710. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/OTT.S265902DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7316074PMC

A Novel Serum Exosomes-Based Biomarker hsa_circ_0002130 Facilitates Osimertinib-Resistance in Non-Small Cell Lung Cancer by Sponging miR-498.

Onco Targets Ther 2020 9;13:5293-5307. Epub 2020 Jun 9.

Department of Respiratory and Critical Medicine, Huaihe Hospital of Henan University, Kaifeng, Henan, People's Republic of China.

Purpose: Exosomes are the effective delivery system for biological compounds, including circular RNAs. In this research, we aimed to explore the role of circular RNA hsa_circRNA_0002130 in osimertinib-resistant non-small cell lung cancer (NSCLC).

Materials And Methods: In our study, the relative protein expression of glucose transporter 1 (GLUT1), hexokinase-2 (HK2) and lactate dehydrogenase A (LDHA) was detected by Western blot, while the expression of hsa_circ_0002130 and microRNA-498 (miR-498) was detected by quantitative real-time PCR (qRT-PCR). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/OTT.S243214DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7293392PMC

p70S6K Promotes Acquired Resistance of Erlotinib Through Induction of Epithelial-Mesenchymal Transition in Non-Small Cell Lung Carcinoma.

Onco Targets Ther 2020 9;13:5257-5270. Epub 2020 Jun 9.

Department of Pharmacology, Nanjing Medical University, Nanjing, Jiangsu Province, People's Republic of China, 210029.

Background: Lung cancer is the leading cause of cancer-related deaths. EGFR tyrosine kinase inhibitors, such as erlotinib, were approved for non-small cell lung carcinoma patients with EGFR mutations. However, the acquired resistance of these inhibitors has not been fully clarified. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/OTT.S249695DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7295111PMC

Tumor Mutational Burden and PD-L1 Expression in Non-Small-Cell Lung Cancer (NSCLC) in Southwestern China.

Onco Targets Ther 2020 8;13:5191-5198. Epub 2020 Jun 8.

Yunnan Cancer Center, The Third Affiliated Hospital of Kunming Medical University, Kunming 650118, People's Republic of China.

Purpose: To explore the impact between the tumor mutational burden (TMB) and programmed death ligand-1 (PD-L1) expression on NSCLC in the Yunnan region of southwestern China.

Patients And Methods: Seventy-one NSCLC specimens that were pathologically confirmed were collected at first. The TMB and driver genetic alterations were evaluated accordingly by next-generation sequencing (NGS). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/OTT.S255947DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7292484PMC

Combination Therapy of Lung Cancer Using Layer-by-Layer Cisplatin Prodrug and Curcumin Co-Encapsulated Nanomedicine.

Drug Des Devel Ther 2020 9;14:2263-2274. Epub 2020 Jun 9.

Department of Oncology Radiotherapy, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, People's Republic of China.

Purpose: Lung cancer remains the leading cancer-associated deaths worldwide. Cisplatin (CDDP) was used in combination with curcumin (CUR) for the treatment of non-small cell lung cancer. The aim of this study was to prepare and characterize CDDP prodrug and CUR co-encapsulated layer-by-layer nanoparticles (CDDP-PLGA/CUR LBL NPs) to induce cooperative response, maximize the therapeutic effect, overcome drug resistance, and reduce adverse side effects. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/DDDT.S241291DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7293387PMC

Combination Chemotherapy of Lung Cancer - Co-Delivery of Docetaxel Prodrug and Cisplatin Using Aptamer-Decorated Lipid-Polymer Hybrid Nanoparticles.

Drug Des Devel Ther 2020 9;14:2249-2261. Epub 2020 Jun 9.

Department of Thoracic Surgery, Fourth Hospital of Hebei Medical University, Tumor Hospital of Hebei Province, Shijiazhuang, Hebei Province, People's Republic of China.

Purpose: Lung cancer is the leading cause of cancer mortality worldwide. Drug resistance is the major barrier for the treatment of non-small cell lung cancer (NSCLC). The aim of this research is to develop an aptamer-decorated hybrid nanoparticle for the co-delivery of docetaxel prodrug (DTXp) and cisplatin (DDP) and to treat lung cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/DDDT.S246574DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7293388PMC

Doublet vs Single-Agent Maintenance Therapy in the Treatment of Non-Small-Cell Lung Cancer: A Meta-Analysis.

Drug Des Devel Ther 2020 3;14:2179-2185. Epub 2020 Jun 3.

Department of Respiration Medicine, Yankuang Group General Hospital, Jining, China.

Background: Several published meta-analyses have confirmed that single-agent maintenance therapy in advanced non-small-cell lung cancer (NSCLC) can prolong time to disease progression and potentially increase overall survival (OS) in comparison to placebo. However, whether doublet maintenance therapy can improve the survival of advanced NSCLC remains undetermined.

Methods: We searched several databases for relevant trials. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/DDDT.S161542DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7294278PMC